Site Search
Professionals 907 results
Capabilities 91 results
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Experience 562 results
Experience
|April 27, 2026
Winston Represents Initial Purchasers in GABX Leasing’s $1 Billion Inaugural Senior Notes Offering
Winston & Strawn LLP represented the initial purchasers, BofA Securities, Inc., MUFG Securities Americas Inc., SMBC Nikko Securities America, Inc., and Wells Fargo Securities, LLC, in connection with GABX Leasing LLC’s inaugural $1 billion Rule 144A offering of senior notes, with GATX Corporation as guarantor. The offering consisted of $500 million of 4.625% Senior Notes due 2031 and $500 million of 5.300% Senior Notes due 2036. GABX Leasing LLC is a joint venture between GATX Corporation and Brookfield Infrastructure Partners L.P. and its institutional partners, formed in connection with the approximately $4.2 billion acquisition of a portfolio of approximately 101,000 railcars from Wells Fargo. This financing represents a key component of the joint venture’s capital structure and supports the continued expansion of one of the largest railcar leasing platforms in North America. This transaction underscores Winston’s market leading capital markets practice and its continued role advising global financial institutions on complex, large scale financings, particularly those supporting critical infrastructure and transportation assets.
Experience
|April 2, 2026
Business Combination and Secured Financing of Keo World and Maha Capital AB
Served as legal counsel to KEO World, Inc., a Miami-based fintech platform specializing in embedded credit and B2B digital payments, in connection with its business combination with Maha Capital AB, a publicly listed investment company on Nasdaq Stockholm. The transaction, which closed on April 2, 2026, was structured as a reverse triangular merger through which KEO World became a wholly owned subsidiary of Maha, with KEO World's parent entity receiving approximately 141 million newly issued Maha shares and nearly 49.2 million earn-out warrants as consideration. In connection with the closing, Maha also executed two directed capital raises totaling USD 27 million at SEK 16 per share and announced a planned third raise of USD 8 million ahead of a contemplated dual listing on a U.S. national securities exchange. Based on publicly available disclosures, the combined transaction has been valued at approximately USD 680 million.
Experience
|March 30, 2026
Winston advised Tikehau Investment Management on the acquisition of a majority stake in GMP Group.
Winston & Strawn LLP Paris advised Tikehau Investment Management on the acquisition of a majority stake in GMP Group. With over 50 years’ experience, GMP Group is a recognised leader in high-precision machining and advanced technologies. Based in Haute-Savoie, the group works with major clients in the aerospace and defence industries. This transaction marks the third acquisition under the latest iteration of Tikehau Capital’s Aerospace & Defence private equity strategy.
Insights & News 6,665 results
Sponsorship
|7 May 2026
Winston Sponsors Sport Resolutions Conference 2026
Winston is pleased to sponsor the annual Sport Resolutions Conference, which will take place at the Leonardo Royal London St Paul’s Hotel.
In the Media
|April 24, 2026
|1 Min Read
The American Lawyer Spotlights Winston’s Momentum with Six Partner Additions
Winston was featured in The American Lawyer following the firm’s addition of six lateral partners across Chicago, New York, Washington, D.C., and Dallas in April, further strengthening key practices including leveraged finance, investigations, intellectual property, and appellate litigation.
In the Media
|April 24, 2026
|1 Min Read
Aimee Fagan Joins Winston in Dallas
Winston & Strawn recently announced that Aimee Fagan has joined the firm’s Dallas office as a partner in the Litigation Department and a member of the Intellectual Property Practice. Aimee is a first-chair trial lawyer whose practice focuses on intellectual property and complex commercial litigation. She represents clients in high-stakes disputes, with significant experience in technology and IP matters, particularly within the energy sector, as well as across the technology, financial services, private equity, medical, and retail industries.
Other Results 128 results
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)